(TWST) Twist Bioscience - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US90184D1000

Stock: Synthetic Genes, Oligo Pools, NGS Tools, Antibody Libraries, Viral Controls

Total Rating 27

Risk 35

Buy Signal 0.58

Diagnostics & Research » Biotechnology
Age: 7.3y

Market Cap: 2,888m
Avg Trading Vol: 55.7M USD

ATR: 5.50%
Peers RS (IBD): 62.00

EPS (Earnings per Share)

EPS CAGR: 27.85%
EPS Trend: 69.2%

Last SUE: -0.26
Qual. Beats: 0

Revenue

Rev. CAGR: 22.72%
Rev. Trend: 98.9%

Last SUE: 1.04
Qual. Beats: 2

Risk 5d forecast
Volatility	68.0%
Relative Tail Risk	-6.95%

Reward TTM
Sharpe Ratio	0.14
Alpha	-31.83

Character TTM
Beta	1.689
Beta Downside	1.115

Drawdowns 3y
Max DD	58.97%
CAGR/Max DD	0.47

Description: TWST Twist Bioscience January 15, 2026

Twist Bioscience (NASDAQ:TWST) is a U.S.-based synthetic DNA manufacturer that produces custom gene fragments, oligo pools, and related reagents for a broad range of applications, including therapeutics, diagnostics, agricultural biotech, and emerging fields such as DNA data storage and computing.

Its product suite spans synthetic genes for drug discovery, next-generation sequencing (NGS) library kits (exome, custom panels, methylation detection), and specialty controls for viral diagnostics (e.g., SARS-CoV-2, monkeypox). The company also offers antibody-engineering solutions and a strategic partnership with bitBiome to expand its microbial-genomics capabilities.

Key quantitative signals (as of FY 2023) include revenue of roughly $400 million, a gross margin near 70 %, and a cash balance exceeding $300 million, which together provide runway for R&D and capacity expansion. The synthetic DNA market is projected to grow at a CAGR of 12-15 % through 2030, driven by accelerating demand for CRISPR-based therapies and large-scale NGS diagnostics-both of which are core end-markets for Twist.

For a deeper quantitative assessment, consult the ValueRay platform’s detailed TWST valuation model.

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income: -76.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.14 > 0.02 and ΔFCF/TA -2.35 > 1.0
NWC/Revenue: 57.06% < 20% (prev 83.49%; Δ -26.42% < -1%)
CFO/TA -0.08 > 3% & CFO -51.0m > Net Income -76.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.78 > 1.5 & < 3
Outstanding Shares: last quarter (61.1m) vs 12m ago 3.24% < -2%
Gross Margin: 51.62% > 18% (prev 0.45%; Δ 5118 % > 0.5%)
Asset Turnover: 62.82% > 50% (prev 54.26%; Δ 8.56% > 0%)
Interest Coverage Ratio: -528.4 > 6 (EBITDA TTM -51.2m / Interest Expense TTM 143.0k)

Altman Z'' -13.21

A: 0.35 (Total Current Assets 303.9m - Total Current Liabilities 80.4m) / Total Assets 638.1m
B: -2.12 (Retained Earnings -1.35b / Total Assets 638.1m)
C: -0.12 (EBIT TTM -75.6m / Avg Total Assets 623.3m)
D: -7.42 (Book Value of Equity -1.35b / Total Liabilities 182.0m)
Altman-Z'' Score: -13.21 = D

Beneish M -2.75

DSRI: 1.07 (Receivables 50.1m/39.3m, Revenue 391.6m/330.2m)
GMI: 0.86 (GM 51.62% / 44.59%)
AQI: 1.41 (AQ_t 0.25 / AQ_t-1 0.17)
SGI: 1.19 (Revenue 391.6m / 330.2m)
TATA: -0.04 (NI -76.6m - CFO -51.0m) / TA 638.1m)
Beneish M-Score: -2.75 (Cap -4..+1) = A

What is the price of TWST shares?

As of February 08, 2026, the stock is trading at USD 49.24 with a total of 2,065,978 shares traded.
Over the past week, the price has changed by +19.89%, over one month by +33.55%, over three months by +60.76% and over the past year by -8.31%.

Is TWST a buy, sell or hold?

Twist Bioscience has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy TWST.

StrongBuy: 6
Buy: 3
Hold: 2
Sell: 1
StrongSell: 0

What are the forecasts/targets for the TWST price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	49.9	1.3%
Analysts Target Price	49.9	1.3%
ValueRay Target Price	50.3	2.1%

TWST Fundamental Data Overview February 07, 2026

P/S = 7.3751
P/B = 6.4687
Revenue TTM = 391.6m USD
EBIT TTM = -75.6m USD
EBITDA TTM = -51.2m USD
Long Term Debt = 98.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.2m USD (from shortTermDebt, last quarter)
Debt = 183.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.87b USD (2.89b + Debt 183.9m - CCE 197.9m)
Interest Coverage Ratio = -528.4 (Ebit TTM -75.6m / Interest Expense TTM 143.0k)
EV/FCF = -33.14x (Enterprise Value 2.87b / FCF TTM -86.7m)
FCF Yield = -3.02% (FCF TTM -86.7m / Enterprise Value 2.87b)
FCF Margin = -22.15% (FCF TTM -86.7m / Revenue TTM 391.6m)
Net Margin = -19.56% (Net Income TTM -76.6m / Revenue TTM 391.6m)
Gross Margin = 51.62% ((Revenue TTM 391.6m - Cost of Revenue TTM 189.4m) / Revenue TTM)
Gross Margin QoQ = 52.05% (prev 51.35%)
Tobins Q-Ratio = 4.50 (Enterprise Value 2.87b / Total Assets 638.1m)
Interest Expense / Debt = 0.08% (Interest Expense 143.0k / Debt 183.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -59.7m (EBIT -75.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.78 (Total Current Assets 303.9m / Total Current Liabilities 80.4m)
Debt / Equity = 0.40 (Debt 183.9m / totalStockholderEquity, last quarter 456.1m)
Debt / EBITDA = -0.69 (negative EBITDA) (Net Debt 35.3m / EBITDA -51.2m)
Debt / FCF = -0.41 (negative FCF - burning cash) (Net Debt 35.3m / FCF TTM -86.7m)
Total Stockholder Equity = 461.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.29% (Net Income -76.6m / Total Assets 638.1m)
RoE = -16.58% (Net Income TTM -76.6m / Total Stockholder Equity 461.8m)
RoCE = -13.50% (EBIT -75.6m / Capital Employed (Equity 461.8m + L.T.Debt 98.0m))
RoIC = -12.93% (negative operating profit) (NOPAT -59.7m / Invested Capital 461.8m)
WACC = 11.42% (E(2.89b)/V(3.07b) * Re(12.14%) + D(183.9m)/V(3.07b) * Rd(0.08%) * (1-Tc(0.21)))
Discount Rate = 12.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.07%
Fair Price DCF = unknown (Cash Flow -86.7m)
EPS Correlation: 69.23 | EPS CAGR: 27.85% | SUE: -0.26 | # QB: 0
Revenue Correlation: 98.93 | Revenue CAGR: 22.72% | SUE: 1.04 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-0.53 | Chg30d=-0.060 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-09-30): EPS=-1.97 | Chg30d=+0.145 | Revisions Net=+0 | Growth EPS=+6.9% | Growth Revenue=+16.6%
EPS next Year (2027-09-30): EPS=-1.89 | Chg30d=+0.165 | Revisions Net=+0 | Growth EPS=+4.3% | Growth Revenue=+15.0%

Additional Sources for TWST Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle